APGE
Apogee Therapeutics Inc.
Latest News for APGE
RBC Capital analyst Brian Abrahams maintained a Buy rating on Apogee Therapeutics on November 10 and set a price target of $70.00. The company’s sh......
Mizuho Securities analyst Joseph Catanzaro maintained a Buy rating on Apogee Therapeutics today and set a price target of $105.00. Catanzaro covers......
In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Apogee Therapeutics, with a price target of $115.00. The compa......
The latest update is out from Apogee Therapeutics ( ($APGE) ). On November 10, 2025, Apogee Therapeutics announced positive interim Phase 1 results......
In a report released on October 27, Joseph Catanzaro from Mizuho Securities maintained a Buy rating on Apogee Therapeutics. The company’s shares cl......
News data is sourced from MarketXLS API and updated regularly.
Showing 5 of 5 articles.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | APGE | $66.26 | +4.6% | 625.60K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Apogee Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW